Evolving Treatment Strategies for Chronic Lymphocytic Leukemia: Insights From Experts Across Mayo Clinic Locations : Episode 10
Key Considerations in Managing Hypertension Risk with BTKis in CLL
Amber Koehler, PA-C, provides expert perspective on addressing hypertension risk in CLL patients undergoing treatment with BTK inhibitors.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
![We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fd5a069c33bbfe917bc7c0b1bb13d76c0a815cc44-234x234.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.")
